{"id":655882,"date":"2023-06-16T08:58:01","date_gmt":"2023-06-16T08:58:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=655882"},"modified":"2023-06-16T08:58:01","modified_gmt":"2023-06-16T08:58:01","slug":"neurofibromatosis-type2-pipeline-clinical-trials-and-emerging-drugs-2023-companies-astrazeneca-recursion-pharma-betta-pharma-novartis-pharma-genentech-takeda-and-others","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/neurofibromatosis-type2-pipeline-clinical-trials-and-emerging-drugs-2023-companies-astrazeneca-recursion-pharma-betta-pharma-novartis-pharma-genentech-takeda-and-others_655882.html","title":{"rendered":"Neurofibromatosis Type-2 Pipeline, Clinical Trials, and Emerging Drugs (2023) | Companies &#8211; AstraZeneca, Recursion Pharma, Betta Pharma, Novartis Pharma, Genentech, Takeda, and others"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1686810058.png\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Neurofibromatosis Type-2 Pipeline, Clinical Trials, and Emerging Drugs (2023) | Companies - AstraZeneca, Recursion Pharma, Betta Pharma, Novartis Pharma, Genentech, Takeda, and others\" src=\"https:\/\/www.abnewswire.com\/uploads\/1686810058.png\" alt=\"Neurofibromatosis Type-2 Pipeline, Clinical Trials, and Emerging Drugs (2023) | Companies - AstraZeneca, Recursion Pharma, Betta Pharma, Novartis Pharma, Genentech, Takeda, and others\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<p style=\"text-align: justify;\">DelveInsight&#8217;s report titled &#8220;Neurofibromatosis Type-2 Pipeline Insight 2023&#8221; offers extensive information on more than 5+ companies and over 5+ pipeline drugs in the field of Neurofibromatosis Type-2 research. The Neurofibromatosis Type-2 pipeline report encompasses detailed profiles of the pipeline drugs for Neurofibromatosis Type-2, including information on Neurofibromatosis Type-2 clinical trials and nonclinical stage products. It also provides a comprehensive assessment of the therapeutics based on product type, stage, route of administration, and molecule type. Additionally, the report highlights the inactive pipeline products in this domain.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">For the Neurofibromatosis Type-2 emerging drugs, the pipeline analysis report presents a comprehensive view of the therapeutic landscape, considering the development stage, product type, route of administration, molecule type, and mechanism of action (MOA). The research on the Neurofibromatosis Type-2 pipeline covers various aspects such as business opportunities, challenges, potential partnerships, strong competitors, and growth strategies. It provides a detailed description of each drug, including its mechanism of action, Neurofibromatosis Type-2 clinical trial studies conducted for Neurofibromatosis Type-2, any NDA approvals obtained for Neurofibromatosis Type-2, and the product development activities encompassing technology, collaborations, licensing, mergers and acquisitions, funding, designations, and other relevant details.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>To explore more information on the latest breakthroughs in the Neurofibromatosis Type-2 Pipeline treatment landscape of the report, click here @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/neurofibromatosis-2-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Neurofibromatosis Type-2 Pipeline Outlook<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Key Takeaways from the Neurofibromatosis Type-2 Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>DelveInsight&rsquo;s Neurofibromatosis Type-2 Pipeline analysis depicts a robust space with 5+ active players working to develop 5+ pipeline treatment therapies.<\/li>\n<li>The leading Neurofibromatosis Type-2 Companies are working in the market include AstraZeneca, Recursion Pharma, Betta Pharma, Novartis Pharma, Genentech, Takeda, and others<\/li>\n<li>Emerging Neurofibromatosis Type-2 Pipeline Therapies in the various stages of development include REC-2282, Icotinib, Endostatin, RAD001, Everolimus, Bevacizumab, Lapatinib, Everolimus (RAD001), Multichannel Auditory Brain Stem Implant, AZD2014, Selumetinib, and others<\/li>\n<li>On February, 2023, Novartis Pharmaceuticals announced a drug name of RAD001, everolimus. The purpose of the study is to determine if RAD001 treatment will shrink or slow the growth of the vestibular schwannoma(s) in Neurofibromatosis 2 (NF2) patients. Secondary objectives include determining if RAD001 treatment will improve hearing ability in NF2 patients.<\/li>\n<li>On March, 2023, Recursion Pharmaceuticals announced a drug name of REC-2282. This is a parallel-group, two-staged, Phase 2\/3, randomized, multi-center study to investigate the efficacy and safety of REC-2282 in patients with progressive NF2 mutated meningiomas.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Neurofibromatosis Type-2 Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Neurofibromatosis 2 (NF2) is a rare genetic disorder that is primarily characterized by noncancerous (benign) tumors of the nerves that transmit balance and sound impulses from the inner ears to the brain (bilateral acoustic neuromas\/vestibular schwannomas). Symptoms may become apparent during childhood, adolescence, and early adulthood or later in adult life.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>For further information, refer to the detailed Neurofibromatosis Type-2 Unmet Needs, Neurofibromatosis Type-2 Market Drivers, and Market Barriers, click here for <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/neurofibromatosis-2-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Neurofibromatosis Type-2 Ongoing Clinical Trial Analysis<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Neurofibromatosis Type-2 Emerging Drugs Profile<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Selumetinib: AstraZeneca<\/li>\n<li>REC-2282: Recursion Pharmaceuticals<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Neurofibromatosis Type-2 Pipeline Therapeutics Assessment<\/strong><\/p>\n<p style=\"text-align: justify;\">There are approx. 5+ Neurofibromatosis Type-2 companies which are developing the therapies for Neurofibromatosis Type 2. The Neurofibromatosis Type-2 companies which have their Neurofibromatosis Type 2 drug candidates in the most advanced stage, i.e. phase II include, AstraZeneca.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request a sample and discover the recent advances in Neurofibromatosis Type-2 Ongoing Clinical Trial Analysis and Medications, click here @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/neurofibromatosis-2-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Neurofibromatosis Type-2 Treatment Landscape<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Neurofibromatosis Type-2 Therapeutics Assessment<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Assessment by Stage and Product Type<\/li>\n<li>Assessment by Route of Administration<\/li>\n<li>Assessment by Stage and Route of Administration<\/li>\n<li>Assessment by Molecule Type<\/li>\n<li>Assessment by Stage and Molecule Type<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of the Companies in the Neurofibromatosis Type-2 Therapeutics Market include-<\/strong><\/p>\n<p style=\"text-align: justify;\">AstraZeneca, Recursion Pharma, Betta Pharma, Novartis Pharma, Genentech, Takeda, and others.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Dive deep into rich insights for drugs for Neurofibromatosis Type-2 Pipeline, click here @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/neurofibromatosis-2-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Neurofibromatosis Type-2 Unmet Needs and Analyst Views<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the Neurofibromatosis Type-2 Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Coverage- Global<\/li>\n<li>Neurofibromatosis Type-2 Companies- AstraZeneca, Recursion Pharma, Betta Pharma, Novartis Pharma, Genentech, Takeda, and others.<\/li>\n<li>Neurofibromatosis Type-2 Therapies- REC-2282, Icotinib, Endostatin, RAD001, Everolimus, Bevacizumab, Lapatinib, Everolimus (RAD001), Multichannel Auditory Brain Stem Implant, AZD2014, Selumetinib, and others<\/li>\n<li>Neurofibromatosis Type-2 Segmentation: Product Type, Molecule Type, Route of Administration<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Got Queries? Find out the related information on Neurofibromatosis Type-2 Mergers and acquisitions, Neurofibromatosis Type-2 Licensing Activities @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/neurofibromatosis-2-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Neurofibromatosis Type-2 Emerging Drugs, and Recent Trends<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Table of Content<\/strong><\/p>\n<ol style=\"text-align: justify;\" start=\"1\">\n<li>Introduction<\/li>\n<li>Neurofibromatosis Type-2 Executive Summary<\/li>\n<li>Neurofibromatosis Type 2: Overview<\/li>\n<li>Neurofibromatosis Type-2 Pipeline Therapeutics<\/li>\n<li>Neurofibromatosis Type-2 Therapeutic Assessment<\/li>\n<li>Neurofibromatosis Type 2 &ndash; DelveInsight&rsquo;s Analytical Perspective<\/li>\n<li>Late Stage Products (Phase III)<\/li>\n<li>Drug name: Company name<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Mid Stage Products (Phase II)<\/li>\n<li>Selumetinib: AstraZeneca<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Early Stage Products (Phase I)<\/li>\n<li>Drug name: Company name<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Preclinical and Discovery Stage Products<\/li>\n<li>Drug name: Company name<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Inactive Products<\/li>\n<li>Neurofibromatosis Type 2 Key Companies<\/li>\n<li>Neurofibromatosis Type 2 Key Products<\/li>\n<li>Neurofibromatosis Type 2- Unmet Needs<\/li>\n<li>Neurofibromatosis Type 2- Market Drivers and Barriers<\/li>\n<li>Neurofibromatosis Type 2- Future Perspectives and Conclusion<\/li>\n<li>Neurofibromatosis Type 2 Analyst Views<\/li>\n<li>Neurofibromatosis Type 2 Key Companies<\/li>\n<li>Appendix<\/li>\n<\/ol>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About Us<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&amp;D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers &amp; Acquisitions.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Yash Bhardwaj<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=neurofibromatosis-type2-pipeline-clinical-trials-and-emerging-drugs-2023-companies-astrazeneca-recursion-pharma-betta-pharma-novartis-pharma-genentech-takeda-and-others\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304  S. Jones Blvd #2432<br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/case-study\/respiratory-domain-conference-coverage\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/case-study\/respiratory-domain-conference-coverage<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/case-study\/respiratory-domain-conference-coverage\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=neurofibromatosis-type2-pipeline-clinical-trials-and-emerging-drugs-2023-companies-astrazeneca-recursion-pharma-betta-pharma-novartis-pharma-genentech-takeda-and-others\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight&#8217;s report titled &#8220;Neurofibromatosis Type-2 Pipeline Insight 2023&#8221; offers extensive information on more than 5+ companies and over 5+ pipeline drugs in the field of Neurofibromatosis Type-2 research. The Neurofibromatosis Type-2 pipeline report encompasses detailed profiles of the pipeline drugs &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/neurofibromatosis-type2-pipeline-clinical-trials-and-emerging-drugs-2023-companies-astrazeneca-recursion-pharma-betta-pharma-novartis-pharma-genentech-takeda-and-others_655882.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[405,406,413],"tags":[],"class_list":["post-655882","post","type-post","status-publish","format-standard","hentry","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/655882","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=655882"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/655882\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=655882"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=655882"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=655882"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}